MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ
4.420
+0.180
+4.25%
After Hours: 4.420 0 0.00% 16:04 05/22 EDT
OPEN
4.280
PREV CLOSE
4.240
HIGH
4.440
LOW
4.260
VOLUME
357.71K
TURNOVER
--
52 WEEK HIGH
6.45
52 WEEK LOW
2.710
MARKET CAP
353.72M
P/E (TTM)
-2.0812
1D
5D
1M
3M
1Y
5Y
1D
Top Atea Pharmaceuticals Insider Quietly Boosts Stake in Bold New Move
TipRanks · 2d ago
Atea director Polly Murphy buys 6,100 shares worth $25,446.15
PUBT · 2d ago
Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley
TipRanks · 5d ago
Weekly Report: what happened at AVIR last week (0511-0515)?
Weekly Report · 5d ago
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
Simply Wall St · 05/14 10:37
Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call
TipRanks · 05/14 00:31
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)
TipRanks · 05/13 13:30
Atea presents new HCV trial data on bemnifosbuvir-ruzasvir at EASL 2026
PUBT · 05/13 11:04
More
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Webull offers Atea Pharmaceuticals Inc stock information, including NASDAQ: AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.